Literature DB >> 22669013

Novel disease-modifying therapies for Alzheimer's disease.

Teng Jiang1, Jin-Tai Yu, Lan Tan.   

Abstract

Alzheimer's disease (AD) is the most common progressive dementia in the elderly and places an enormous burden on the individual and society. Presently, the treatments for AD are only symptomatic and do not halt the progression of the disease. With the recent advances in the understanding of the pathogenesis of AD in past years, numerous therapies which could modify the disease process are under active investigation. These therapies could attenuate or even reverse the neurodegenerative process by interfering with the underlying pathogenesis including amyloid-β production, tau hyperphosphorylation, oxidative stress, inflammation, and excitotoxicity. In this review, new disease-modifying therapies which reduce amyloid-β production, prevent tau hyperphosphorylation, and provide neuroprotective effects are described, including the results of in vitro and in vivo studies and clinical trials. Some typical therapies with disease-modifying effects have also been discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669013     DOI: 10.3233/JAD-2012-120640

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  35 in total

Review 1.  Microglial priming in Alzheimer's disease.

Authors:  Jun-Wei Li; Yu Zong; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

2.  Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease.

Authors:  Teng Jiang; Ying-Dong Zhang; Jun-Shan Zhou; Xi-Chen Zhu; You-Yong Tian; Hong-Dong Zhao; Huan Lu; Qing Gao; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-06-05       Impact factor: 5.590

3.  Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals.

Authors:  Xiaolong Zhang; Jin-Tai Yu; Jin Li; Chao Wang; Lan Tan; Bing Liu; Tianzi Jiang
Journal:  Neuropsychopharmacology       Date:  2015-01-29       Impact factor: 7.853

Review 4.  CR1 in Alzheimer's disease.

Authors:  Xi-Chen Zhu; Jin-Tai Yu; Teng Jiang; Ping Wang; Lei Cao; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

Review 5.  Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.

Authors:  Lei Cao; Lan Tan; Teng Jiang; Xi-Chen Zhu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

6.  Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Authors:  Lei Cao; Hui-Fu Wang; Lin Tan; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2016-03-22

Review 7.  β-Arrestins as potential therapeutic targets for Alzheimer's disease.

Authors:  Teng Jiang; Jin-Tai Yu; Meng-Shan Tan; Xi-Chen Zhu; Lan Tan
Journal:  Mol Neurobiol       Date:  2013-05-16       Impact factor: 5.590

8.  GWAS-Linked Loci and Neuroimaging Measures in Alzheimer's Disease.

Authors:  Jie-Qiong Li; Hui-Fu Wang; Xi-Chen Zhu; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

Review 9.  Toward precision medicine in neurological diseases.

Authors:  Lin Tan; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2016-03

Review 10.  TYROBP in Alzheimer's disease.

Authors:  Jing Ma; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-07-23       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.